The estimated Net Worth of Woodrow A Jr Myers is at least $405 Thousand dollars as of 1 March 2024. Woodrow Myers owns over 10,000 units of Personalis Inc stock worth over $155,390 and over the last 19 years Woodrow sold PSNL stock worth over $249,327.
Woodrow has made over 5 trades of the Personalis Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Woodrow bought 10,000 units of PSNL stock worth $16,700 on 1 March 2024.
The largest trade Woodrow's ever made was exercising 41,250 units of Personalis Inc stock on 14 February 2013 worth over $778,800. On average, Woodrow trades about 2,041 units every 103 days since 2006. As of 1 March 2024 Woodrow still owns at least 26,116 units of Personalis Inc stock.
You can see the complete history of Woodrow Myers stock trades at the bottom of the page.
Woodrow's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci, and Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: